Shots:

• The approval is based on P-III IBS-C program includes Trial 1 (NCT02686138) and Trial 2 (NCT02621892) which involve assessing of Ibsrela vs PBO in patients with abdominal pain and bowel movement frequency
• The P-III IBS-C program met all 1EPs including Trial 1 and 2 (37%- 27% vs 24%- 19%)- discontinuation rates (7.6% vs 0.8%)
• Ibsrela (50 mg- bid) is an orally administered drug involves inhibiting of sodium/hydrogen exchanger 3 (NHE3) targeted for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults

Click here to­ read full press release/ article | Ref: Ardelyx | Image: Twitter